Valo Health to Present at the 41st Annual J.P. Morgan Healthcare Conference

Valo Health, Inc. (“Valo”), the tech­nol­o­gy com­pa­ny using human-cen­tric data and arti­fi­cial intel­li­gence (AI) pow­ered com­pu­ta­tion to trans­form the drug dis­cov­ery and devel­op­ment process, today announced that it will par­tic­i­pate in the 41^st Annu­al J.P. Mor­gan Health­care Con­fer­ence in San Fran­cis­co, Jan­u­ary 9^th – 12^th.

David Berry, M.D. PhD, Val­o’s CEO and founder is sched­uled to present on Tues­day, Jan­u­ary 10, 2023, at 2:30 PM PT (5:30 PM ET) in the Gold­en Gate Room (31^st Fl) at the West­in St. Fran­cis in San Francisco.

Val­o’s man­age­ment, investor rela­tions, and busi­ness devel­op­ment lead­er­ship will be attend­ing and avail­able through­out the con­fer­ence for meetings. 

About Valo Health
Valo Health, Inc (“Valo”) is a tech­nol­o­gy com­pa­ny built to trans­form the drug dis­cov­ery and devel­op­ment process using human-cen­tric data and arti­fi­cial intel­li­gence-dri­ven com­pu­ta­tion. As a dig­i­tal­ly native com­pa­ny, Valo aims to ful­ly inte­grate human-cen­tric data across the entire drug devel­op­ment life cycle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing costs, time, and fail­ure rates. The com­pa­ny’s Opal Com­pu­ta­tion­al Plat­form^™ is an inte­grat­ed set of capa­bil­i­ties designed to trans­form data into valu­able insights that may accel­er­ate dis­cov­er­ies and enable Valo to advance a robust pipeline of pro­grams across car­dio­vas­cu­lar meta­bol­ic renal, oncol­o­gy, and neu­rode­gen­er­a­tive dis­ease. Found­ed by Flag­ship Pio­neer­ing and head­quar­tered in Boston, MA, Valo also has offices in Lex­ing­ton, MA, New York, NY, and San Fran­cis­co, CA.